NDC 70518-0341

Atripla

Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Atripla is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Remedyrepack Inc.. The primary component is Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate.

Product ID70518-0341_83d3e414-dbf9-9cb6-e053-2a91aa0aa3c9
NDC70518-0341
Product TypeHuman Prescription Drug
Proprietary NameAtripla
Generic NameEfavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2017-03-20
Marketing CategoryNDA / NDA
Application NumberNDA021937
Labeler NameREMEDYREPACK INC.
Substance NameEFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Active Ingredient Strength600 mg/1; mg/1; mg/1
Pharm ClassesHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [EXT],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 70518-0341-0

30 TABLET, FILM COATED in 1 BLISTER PACK (70518-0341-0)
Marketing Start Date2017-03-20
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 70518-0341-0 [70518034100]

Atripla TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA021937
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-03-20

Drug Details

Active Ingredients

IngredientStrength
EFAVIRENZ600 mg/1

OpenFDA Data

SPL SET ID:5e308bec-7277-4cea-a112-f86839f64609
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 643070
  • 643066
  • Pharmacological Class

    • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Non-Nucleoside Analog [EXT]
    • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Cytochrome P450 3A Inducers [MoA]
    • Cytochrome P450 2B6 Inducers [MoA]
    • Cytochrome P450 2C9 Inhibitors [MoA]
    • Cytochrome P450 2C19 Inhibitors [MoA]
    • Cytochrome P450 3A4 Inhibitors [MoA]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

    NDC Crossover Matching brand name "Atripla" or generic name "Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate"

    NDCBrand NameGeneric Name
    15584-0101Atriplaefavirenz, emtricitabine, and tenofovir disoproxil fumarate
    50090-0980Atriplaefavirenz, emtricitabine, and tenofovir disoproxil fumarate
    53808-0208Atriplaefavirenz, emtricitabine, and tenofovir disoproxil fumarate
    70518-0341Atriplaefavirenz, emtricitabine, and tenofovir disoproxil fumarate

    Trademark Results [Atripla]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ATRIPLA
    ATRIPLA
    78595551 3276743 Live/Registered
    GILEAD SCIENCES LLC
    2005-03-25

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.